TAP binding protein likeGenealiases: TAPBP-R · TAPBPR
Q-omics provides the consensus-scored TAPBPL profile across patient tissues and cancer cell-line models. TAPBPL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TAPBPL is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TAPBPL RNA expression shows 17,258 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where TAPBPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAPBPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAPBPL survival associations across molecular data types. TAPBPL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAPBPL RNA expression–survival associations across cancer types. High TAPBPL expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, BLCA, BRCA and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TAPBPL RNA expression.
This table summarizes TAPBPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TAPBPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAPBPL shows lower tumor expression in THCA, LUAD and LUSC and higher tumor expression in KIRC, HNSC and KIRP. The THCA box plot shows higher TAPBPL RNA expression in normal versus tumor tissue (log2 FC = −1.251, t-test p < 0.001).
This table shows molecular features associated with TAPBPL in patient tissues and cancer cell lines. In patient samples, TAPBPL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAPBPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
